https://scholars.lib.ntu.edu.tw/handle/123456789/634957
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Kim, Hye Ryun | en_US |
dc.contributor.author | Sugawara, Shunichi | en_US |
dc.contributor.author | Lee, Jong-Seok | en_US |
dc.contributor.author | Kang, Jin-Hyoung | en_US |
dc.contributor.author | Inui, Naoki | en_US |
dc.contributor.author | Hida, Toyoaki | en_US |
dc.contributor.author | Lee, Ki Hyeong | en_US |
dc.contributor.author | Yoshida, Tatsuya | en_US |
dc.contributor.author | Tanaka, Hiroshi | en_US |
dc.contributor.author | Yang, Cheng-Ta | en_US |
dc.contributor.author | Nishio, Makoto | en_US |
dc.contributor.author | Ohe, Yuichiro | en_US |
dc.contributor.author | Tamura, Tomohide | en_US |
dc.contributor.author | Yamamoto, Nobuyuki | en_US |
dc.contributor.author | CHONG-JEN YU | en_US |
dc.contributor.author | Akamatsu, Hiroaki | en_US |
dc.contributor.author | Takahashi, Shigeru | en_US |
dc.contributor.author | Nakagawa, Kazuhiko | en_US |
dc.date.accessioned | 2023-09-04T06:49:27Z | - |
dc.date.available | 2023-09-04T06:49:27Z | - |
dc.date.issued | 2023-08-28 | - |
dc.identifier.issn | 2045-7634 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/634957 | - |
dc.description.abstract | ONO-4538-52/TASUKI-52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first-line) treatment of patients with advanced non-squamous non-small cell lung cancer (nsNSCLC). At the interim analysis (minimum follow-up, 7.4 months), the independent radiology review committee-assessed progression-free survival was significantly longer in the nivolumab arm, but overall survival (OS) data were immature. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Cancer medicine | en_US |
dc.subject | bevacizumab; chemotherapy; nivolumab; non-squamous non-small cell lung cancer; survival | en_US |
dc.title | First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1002/cam4.6348 | - |
dc.identifier.pmid | 37641544 | - |
dc.identifier.scopus | 2-s2.0-85169072695 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85169072695 | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | National Taiwan University Hospital Hsin-Chu Branch | - |
crisitem.author.dept | NTU BioMedical Park Hospital | - |
crisitem.author.orcid | 0000-0001-5664-9392 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital Hsin-Chu Branch | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。